Brinzolamide
| Clinical data | |
|---|---|
| Pronunciation | brin ZOH la mide |
| Trade names | Azopt |
| Other names | (5R)-5-ethylamino-3-(3-methoxypropyl)- 2,2-dioxo-2λ6,9-dithia- 3-azabicyclo[4.3.0]nona-7,10-diene- 8-sulfonamide |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601233 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Absorbed systemically, but below detectable levels (less than 10 ng/mL) |
| Protein binding | ~60% |
| Elimination half-life | 111 days |
| Excretion | Kidney (60%) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.149.376 |
| Chemical and physical data | |
| Formula | C12H21N3O5S3 |
| Molar mass | 383.50 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Brinzolamide (trade name Azopt) is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Brinzolamide was approved as a generic medication in the United States in November 2020.[2]
- ^ "Brinzolamide ophthalmic (Azopt) Use During Pregnancy". Drugs.com. 16 May 2019. Retrieved 17 August 2020.
- ^ "First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 12 June 2019. Retrieved 13 February 2021.